Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), announced an open casting call for individuals to share their personal BOTOX® Cosmetic stories. This initiative supports their ongoing 'See Yourself' campaign aimed at fostering an authentic dialogue regarding aesthetic treatments. The casting call is open until March 2022, with a goal to reach even more consumers than the nearly one billion reached in 2021. Finalists will participate in a nationwide advertising campaign across various digital platforms.
AbbVie announced the FDA approval of SKYRIZI (risankizumab-rzaa) for treating adults with active psoriatic arthritis (PsA). This approval follows data from pivotal studies, KEEPsAKE-1 and KEEPsAKE-2, showing significant efficacy compared to placebo in joint pain and other symptoms. SKYRIZI features a convenient dosing regimen of one injection every three months after initial doses. It aims to alleviate both skin and joint symptoms, improving quality of life for approximately 30% of psoriasis patients who experience PsA.
AbbVie announced that the FDA approved RINVOQ® (upadacitinib) for treating moderate to severe atopic dermatitis in adults and children aged 12 and older. This approval is significant for patients unresponsive to previous treatments, providing a once-daily oral option. Supported by data from over 2,500 patients in Phase 3 trials, RINVOQ demonstrated strong efficacy, with up to 80% of patients achieving significant skin clearance. However, it carries risks of serious infections and cardiovascular issues. AbbVie aims to improve patient access through support programs.
AbbVie confirms its revenue guidance for 2025, projecting combined risk-adjusted sales exceeding $15 billion from Rinvoq and Skyrizi. The forecast includes more than $7.5 billion in sales for each product. Adjustments were made due to lower sales expectations for Rinvoq in the U.S. after label updates, balanced by increased international sales and higher demand in Crohn's disease and ulcerative colitis, following positive Phase 3 study results. Skyrizi's growth is attributed to strong performance in psoriasis.
On January 11, 2022, ACELYRIN, INC. appointed Melanie Gloria as the new Chief Operating Officer (COO). With over 20 years in biotechnology, Gloria previously held senior roles at Abbott, AbbVie, and Horizon Therapeutics, leading R&D functions and achieving global therapy approvals. Her extensive background in drug development includes multiple therapeutic areas such as oncology and immunology. The leadership team believes Gloria's experience will enhance ACELYRIN's pursuit of life-changing treatments and support its growth strategy.
AbbVie has submitted applications for upadacitinib (RINVOQ®) to the FDA and EMA to treat adults with active non-radiographic axial spondyloarthritis (nr-axSpA) who inadequately respond to NSAIDs. Based on the Phase 3 SELECT-AXIS 2 trial, upadacitinib showed efficacy in reducing symptoms and improving physical function. Additionally, AbbVie requested label enhancements for upadacitinib in the EU for active ankylosing spondylitis (AS). The safety profile remained consistent with previously known data, with no new risks identified.
AbbVie (NYSE: ABBV) is set to report its fourth-quarter and full-year 2021 financial results on February 2, 2022, before market opening. A live webcast of the earnings call will occur at 8 a.m. CT on the same day, accessible via AbbVie's Investor Relations website. Following the event, an archived version will be available for later viewing. AbbVie focuses on delivering innovative medicines across various therapeutic areas including immunology, oncology, and neuroscience.
AbbVie (NYSE: ABBV) has received Breakthrough Therapy Designation (BTD) from the FDA for its investigational drug telisotuzumab vedotin (Teliso-V). This designation targets patients with advanced/metastatic non-small cell lung cancer (NSCLC) characterized by high c-Met overexpression and disease progression post-platinum therapy. Teliso-V aims to address the significant unmet medical needs in NSCLC treatments. Data from the ongoing Phase 2 study (LUMINOSITY) shows promising preliminary efficacy, with an overall response rate of 53.8% among patients with c-Met overexpressing tumors.
AbbVie (NYSE: ABBV) is set to participate in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 2:45 p.m. CT. Key executives, including Robert A. Michael, Michael E. Severino, M.D., and Jeffrey R. Stewart, will present virtually. A live audio webcast will be accessible on AbbVie's Investor Relations website, with an archived session available later that day. AbbVie focuses on innovative medicines across various therapeutic areas including immunology and oncology.
On December 16, 2021, Allergan Aesthetics, part of AbbVie (NYSE: ABBV), completed its acquisition of Soliton, Inc. (NASDAQ: SOLY). This acquisition enhances Allergan's offering of non-invasive body contouring solutions by adding the RESONIC™ device, which is FDA-cleared for long-term cellulite improvement and tattoo removal. Clinical data showed that 97.6% of participants reported significant cellulite improvement post-treatment. The acquisition reflects Allergan's commitment to innovation in aesthetic treatments, addressing consumer concerns about cellulite.